Stockreport

Delcath outlines 40 active center target and 150% HEPZATO treatment volume growth for 2025 amid CHOPIN data momentum [Seeking Alpha]

Delcath Systems, Inc.  (DCTH) 
US:NASDAQ Investor Relations: delcath.com/investors
PDF CEO Gerard Michel highlighted the "compelling results from the investigator-sponsored CHOPIN trial" and announced the first patient dosed in the company's colorectal ca [Read more]